Agios (AGIO) Q2 2025 Earnings Call Transcript [Globe and Mail, The (Toronto, Canada)]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Globe and Mail, The
Chief Financial Officer — Cecilia Jones Chief Commercial Officer — Tsveta Milanova Chief Medical Officer — Sarah Gheuens Need a quote from a Motley Fool analyst? Email pr@fool.com TAKEAWAYS Net Revenue -- $12.5 million, representing 45% year-over-year growth and a 44% sequential increase from $8.7 million in the prior quarter, driven by continued commercial execution in PKD, an extra week of ordering, and more units processed by the specialty pharmacy. PYRUKYND Patient Enrollment -- 248 patients completed prescription enrollment forms as of quarter-end, up 6% sequentially, with 142 patients on active treatment, a 4% sequential increase. Cash and Equivalents -- Approximately $1.3 billion at quarter-end, supporting pipeline advancement and commercial build-out activities. Cost of Sales -- $1.7 million for the quarter. R&D Expense -- $91.9 million, up $14.5 million year over year, including a $10 million milestone payment to Alnylam for AG-236 development. SG&A Expen
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios (AGIO) Q3 2025 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Agios Pharmaceuticals (AGIO) had its price target lowered by Bank of America Corporation from $44.00 to $41.00. They now have a "buy" rating on the stock.MarketBeat
- Here's Why Agios Pharmaceuticals Crashed 23% Today [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Agios Pharmaceuticals (AGIO) had its price target lowered by HC Wainwright from $65.00 to $50.00. They now have a "buy" rating on the stock.MarketBeat
- Agios Pharmaceuticals (AGIO) had its price target raised by JPMorgan Chase & Co. from $31.00 to $36.00. They now have a "neutral" rating on the stock.MarketBeat
AGIO
Earnings
- 2/12/26 - Miss
AGIO
Sec Filings
- 4/6/26 - Form 4
- 4/6/26 - Form 4
- 4/6/26 - Form 4
- AGIO's page on the SEC website